The present investigation evaluated the effects of LMWGAL-TF) on human subjects with high fat mass for 8-weeks using a prospective, randomized, double-blind, placebo-controlled design. Twenty-four subjects with percent body fat were randomized to ingest a capsule of LMWGAL-TF (500 mg, once a day) or the matching placebo at a 1:1 ratio for 8 weeks. The outcome measurements were recorded at baseline, week-4 and week-8 (end of the treatment). The efficacy outcome included fat mass (absolute, non-fat mass and %) and by skinfold thickness method (along with triceps, suprailiac and abdominal) and boelectrical impendence analysis (BIA) method, body weight, body mass index (BMI) and abdominal girth. The standard safety parameters were measured such as adverse events, vital signs, hematology, and biochemistry. Eight weeks of LMWGAL-TF supplementation showed significant reduction in absolute non-fat mass (changes from baseline) by both skinfold thickness and BIA methods(v/s Placebo), abdominal skin fold thickness (v/s Placebo) and percent fat mass, and skin fold thickness (abdominal and suprailiac) (values v/s baseline). The LMWGAL-TF supplementation was found to be safe and well-tolerated. In conclusion, LMWGAL-TF supplementation showed safety and efficacy in reducing absolute non-fat mass and skin fold thickness in subjects with a high fat mass.
Key words: Fenugreek seed; low molecular weight galactomannans; fat mass; skinfold thickness; obesity
|
